Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer
This phase II trial compares the effect of oxybutynin versus placebo for reducing hot flashes in men receiving androgen deprivation (hormone) therapy for the treatment of prostate cancer . Androgen deprivation therapy decreases testosterone and other androgens through medications or surgical removal of the testicles. Relative to placebo, low- or high-dose oxybutynin may reduce hot flashes in men receiving androgen deprivation therapy.
Research Base: Alliance for Clinical Trials in Oncology
NCT ID: NCT04600336
NCI Protocol Number: A222001
Status: Active, not recruiting
For more information see ClinicalTrials.gov
Interventions
- Oxybutynin Chloride
- Placebo Administration
- Quality-of-Life Assessment
- Questionnaire Administration
Condition
Prostate Carcinoma
Trial Type
Supportive Care/Symptom Management/PROs
See a list of participating sites on ClinicalTrials.gov